Oncology
Page 3 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
![NMPA Approval [Drug Name]: Impact on China’s Oncology Market 2025](/uploads/articles/nmpa-approval-drugname-oncology-market-analysis-2025.webp)
NMPA Approval [Drug Name]: Impact on China’s Oncology Market 2025
The NMPA's approval of Drug Name marks a significant milestone for China's oncology market in 2025, promising enhanced treatment options for cancer patients.
Kelun-Biotech's Sacituzumab Tirumotecan and Two Other Cancer Drugs Selected for ASCO 2026 Oral Presentations
Kelun-Biotech announces three clinical studies selected for oral presentations at ASCO 2026, including TROP2 ADC sacituzumab tirumotecan results.
Turbine Partners with Crown Bioscience to Advance AI-Powered Cancer Drug Discovery Using Organoid Technology
Turbine and Crown Bioscience announce strategic partnership combining AI virtual screening with organoid tumor models to accelerate oncology research and drug development.
Chinese-Developed ADCs Integration: Clinical Impact & Regulatory Advances in APAC
This article delves into the integration of Chinese-developed antibody-drug conjugates (ADCs) and their significant clinical and regulatory advancements in the APAC region.
APAC KRAS Inhibitors: Elisrasib’s Promise in Advanced NSCLC
Elisrasib emerges as a promising KRAS inhibitor, revolutionizing treatment options for advanced NSCLC in the APAC region.
Rznomics RZ-001 Shows 61.5% Response Rate in Hepatocellular Carcinoma Trial at AACR 2026
Rznomics reports encouraging interim data for RZ-001 RNA editing therapy in liver cancer, showing 61.5% response rate with favorable safety profile at AACR 2026.
Radioligand Therapies for Prostate Cancer: Market Access and Clinical Insights in APAC
This article delves into the landscape of radioligand therapies for prostate cancer, focusing on market access and clinical insights across the APAC region.
Australian Biotech Solid Tumor CAR-T: What You Need to Know
Explore the advancements in Australian Biotech's CAR-T therapy for solid tumors, offering new hope for patients battling cancer with innovative treatment options.
NMPA Approval Oncology Drugs: Accelerated & Conditional Pathways Explained
This article delves into the NMPA's accelerated and conditional pathways for oncology drugs, highlighting their significance in expediting approvals for critical treatments.
ACT Genomics Expands Cancer Genomic Testing Panel to 101 Genes with 7-Day Turnaround Time
ACT Genomics upgrades ACTDrug genomic testing to 101-gene panel with 7-day results for advanced cancer patients, enhancing precision medicine capabilities.
Antengene Presents Three Novel Cancer Programs at AACR 2026: Next-Generation ADC and TCE Therapies Show Promise
Antengene Corporation unveiled three innovative cancer treatment programs at AACR 2026, featuring next-generation ADC and TCE technologies for oncology patients.
Antengene Presents Next-Generation ADC and AnTenGager TCE Programs at AACR 2026
Antengene showcases three novel oncology programs at AACR 2026, featuring next-generation ADC technology and AnTenGager T-cell engagers for cancer treatment.